XM does not provide services to residents of the United States of America.
A
A

AlaskaAir

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

New Boeing CEO holds first meeting with FAA chief

New Boeing CEO holds first meeting with FAA chief WASHINGTON, Aug 30 (Reuters) - New Boeing CEO Kelly Ortberg met earlier this week with the head of the Federal Aviation Administration as the planemaker faces numerous regulatory issues and increased scrutiny, an agency official confirmed Friday. Ortberg told employees Friday in an email he had met with the FAA this week and discussed the company's safety and quality plan.
B
A

U.S. STOCKS Catalent, Tesla, Sezzle

BUZZ-U.S. STOCKS ON THE MOVE-Catalent, Tesla, Sezzle Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The tech-heavy Nasdaq led Wall Street's main indexes higher on Thursday after data showed a still robust U.S. economy, while AI chip firm Nvidia slipped as its largely in-line forecast failed to meet lofty expectations of investors.
B
J
M
T
U
U
U
A

U.S. STOCKS Cooper Companies, Catalent, Tesla

BUZZ-U.S. STOCKS ON THE MOVE-Cooper Companies, Catalent, Tesla Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes rose on Thursday, led by the tech-heavy Nasdaq, as investors were relieved after data showed a still robust U.S.
C
G
G
J
M
N
N
T
A
A
D
U
U
A

Citigroup cuts Alaska Air PT, adjusts Q4 unit cost forecast

BUZZ-Citigroup cuts Alaska Air PT, adjusts Q4 unit cost forecast ** Citigroup cuts Alaska Air's ALK.N PT by $3 to $48 ** Brokerage says is adjusting ALK's Q4 unit cost forecast to incorporate potential agreement with flight attendants ** 10 of 14 brokerages rate the stock "buy" or higher, 4 "hold" ** Up to Wednesday's close, stock had fallen ~8.5%
A

U.S. Centerspace, Neurocrine Biosciences, 1-800-Flowers.com

U.S. RESEARCH ROUNDUP-Centerspace, Neurocrine Biosciences, 1-800-Flowers.com Aug 29 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Centerspace, Neurocrine Biosciences and Veeva Systems, on Thursday. HIGHLIGHTS * Air Products APD.N : Berenberg raises target price to $275 from $240 * Centerspace CSR.N : Raymond James raises target price to $82 from $75 * Neurocrine Biosciences Inc NBIX.O : Piper Sandler raises to over
A
G
M
N
N
S
A
D
E
E
A
E
P

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.